tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Oruka Therapeutics initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $46 price target The firm views the stock’s valuation as “compelling” following the 67% drop year-over-year. Oruka’s “superior assets” are positioned to win market share in psoriasis, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1